Durbin/Hatch bill
HHS Secretary Michael Leavitt has promised to examine legislation mandating adverse event reporting for dietary supplements and OTC drugs, Sen. Richard Durbin (D-Ill.), notes during Jan. 26 confirmation hearing. Durbin and Sen. Orrin Hatch (R-Utah) are working together to create an AER bill with input from industry (1"The Tan Sheet" June 28, 2004, p. 3). "There should be a clearinghouse at FDA for manufacturers to provide data about the safety of their products," Durbin says. "As we develop legislation this year, Leavitt has agreed to review it"...
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.